Approximately one in every eight American adults is currently taking a GLP-1 receptor agonist — drugs such as Ozempic, Zepbound, and Wegovy — and the cumulative effect on how those tens of millions of people eat, shop, and choose restaurants is beginning to register as a measurable structural force across the food and beverage industry.³⁴ With the GLP-1 user population sitting at around 10 million Americans in 2026 and projected to exceed 30 million by 2030, the food industry is confronting a question it has not faced before: how do you sell food to customers who have been pharmacologically recalibrated to want significantly less of it?¹⁹

How GLP-1 drugs change eating behaviour

GLP-1 drugs work by mimicking a gut hormone that suppresses appetite, slows gastric emptying, and signals satiety to the brain. The behavioural consequences for food consumption are substantial: studies show that GLP-1 users reduce their total calorie intake by approximately 30%, driven by the combination of appetite suppression and the physical sensation of fullness arriving much earlier than it previously did.³⁵ Around half of all GLP-1 users report consuming noticeably fewer calories while on the medications, and approximately 70% of those who eat less report that they are snacking significantly less.³

The changes in what people eat are as significant as the changes in how much. GLP-1 users report shifting their purchases toward more fresh produce and high-protein items, while cutting back on sweets, salty snacks, and sugary beverages — the categories that generate the highest margins for packaged food manufacturers and convenience operators.³⁶ The foods people tend to crave less on GLP-1 drugs are, in many cases, precisely the foods that the processed food industry has spent decades engineering to be maximally appealing.⁷¹⁰

The impact on restaurants

The restaurant sector is feeling the effect most acutely in the evening. Research cited by Bloomberg in May 2026 found that dinner traffic has fallen 6% among consumers who have been taking GLP-1 medications regularly, translating into an approximately 0.4% decline in overall restaurant dinner sales attributable to GLP-1 use across the industry.⁴¹ At current adoption rates this may appear modest, but the trajectory matters: as GLP-1 use expands, the suppression effect on high-frequency dining occasions — particularly calorie-dense casual dining — is expected to compound.⁵⁹

Restaurant operators are responding by experimenting with smaller portion formats, higher-protein menu items, and dishes emphasising quality and ingredient provenance over sheer caloric abundance.¹⁸ The trend is visible in the National Restaurant Association's 2026 FABI Award selections, where protein-forward products took the top honours and plant-based alternatives — which had previously dominated the innovation conversation — receded from the foreground.²

How food manufacturers are adapting

Food and beverage companies across the sector are racing to position their products for a GLP-1-mediated market. Bloomberg's May 2026 investigation found that protein-rich frozen meals are seeing accelerated growth as GLP-1 users look for convenient, nutritionally dense options that satisfy in smaller portions.⁴ Several companies have begun labelling products as "GLP-1 friendly" or reformulating existing lines to increase protein and fibre content, reduce serving size, and reduce added sugar — attempting to align with the dietary profile that GLP-1 users are gravitating toward naturally.⁶⁷

The long-term market signal is large. Food Dive has reported that GLP-1 users are projected to account for 35% of total food and beverage sales by 2030, a figure that would make understanding and serving this cohort an existential strategic priority for major food companies rather than a niche product line decision.⁹ Companies that adapt their product portfolios now — reformulating for nutritional density, shrinking portions, and emphasising protein — will be better positioned than those that wait to react once the market shift becomes undeniable.⁸¹⁰

The limits and unknowns

Not all analysts are convinced the GLP-1 effect on food will be as sweeping as the most bullish projections suggest. FoodNavigator has reported evidence of demand deceleration for GLP-1 drugs themselves as concerns grow about side effects, supply constraints, and insurance coverage gaps that limit access for lower-income consumers.⁶ If GLP-1 penetration plateaus significantly below 30 million users, the impact on the food industry will be real but bounded rather than transformational.¹⁰ The deeper uncertainty is whether the eating habit changes GLP-1 drugs produce are durable after people stop taking the medication — a question the clinical evidence base has not yet resolved.⁷

#ozempic

How GLP-1 Weight-Loss Drugs Are Quietly Reshaping What America Eats — and Forcing the Food Industry to Reinvent Itself